前收市價 | 2.3500 |
開市 | 4.9000 |
買盤 | 0.0000 |
賣出價 | 0.0000 |
拍板 | 35.00 |
到期日 | 2024-08-16 |
今日波幅 | 2.1000 - 4.9000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 無 |
BridgeBio stock gave up gains midday Tuesday after releasing a Phase 2 study on a growth disorder treatment.
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let’s get some of the bad stuff out of the way first. Biotech stocks – even the established players – can be volatile. A miss in the clinical process to commercialize a therapeutic could lead to significant losses. And there’s really no way of reliably forecasting such outcomes. Plus, the sector isn’t always known for delivering predictable financi
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.